Status:

RECRUITING

Migration in Total Hip Arthroplasty with a Cemented BiMobile Cup: Better Stability with More Cement?

Lead Sponsor:

JointResearch

Conditions:

Total Hip Arthroplasty

Osteoarthritis, Hip

Eligibility:

All Genders

65+ years

Phase:

NA

Brief Summary

Objective: The main objective of this study is to compare the (early) migration of the cemented BiMobile cup at two year post-surgery between two different cup sizes after standard optimal reaming, an...

Detailed Description

Rationale: Total hip arthroplasty (THA) is a commonly performed surgery in patients with end-stage osteoarthritis (OA) of the hip. Although it is known as a successful procedure, (recurrent) dislocati...

Eligibility Criteria

Inclusion

  • Patient requiring an elective primary cemented THA.
  • Male patient ≥70 years old and female patient ≥65 years old.
  • Ability and willingness to follow instructions and to return for follow-up evaluations.
  • The patient is able to understand the meaning of the study and is willing to sign informed consent.
  • Understanding the Dutch language.

Exclusion

  • The patient is morbidly obese, defined as Body Mass Index (BMI) of ≥ 40.
  • The patient is expected to need lower limb joint replacement for another joint within one year.
  • The patient has a systemic or metabolic disorder leading to progressive bone deterioration.
  • The patient has a deformity or disease located in other joints than the hip that needs surgery and that is limiting their ability to walk.
  • The patient has an active or suspected latent infection in or around the hip joint.
  • The patient's bone stock is compromised by a disease or infection which cannot provide adequate support and/or fixation to the prosthesis.
  • The patient is unable or unwilling to sign informed consent for this study.
  • The patient is deemed unsuitable for participation in the study based on the investigator's judgment.

Key Trial Info

Start Date :

January 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2029

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT04049279

Start Date

January 1 2019

End Date

May 1 2029

Last Update

February 28 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

OLVG

Amsterdam, Netherlands, 1091 AC